Shares of medical diagnostics company Rhythm Biosciences (ASX:RHY) witnessed a surge as high as 15% to A$0.345, marking their notably rise in intraday percentage gain since 23rd August.

The stock is now at its highest level since 15th September, according to recent changes.

Rhythm Biosciences (ASX:RHY) announced preliminary results from its Agilex Stage 1 study, which showed promising outcomes.

It was able to identify four biomarkers, combinations that can effectively differentiate between breast cancer patients and healthy individuals, delivering a sensitivity of 83% and a specificity of 90%.

In the wave of this announcement, nearly 455,500 shares were traded, a significant push compared to the 30-day average volume of 177,596.

Despite a 69.7% decline in stock value year-to-date, as of the last closing, it competed against the 1.7% rise in the benchmark S&P/ASX 200 index.

Rhythm Biosciences (ASX:RHY) is a company that specializes in medical diagnostics.